Neurelis announced today that it closed a $114 million Series D financing round to support its lead orphan drug product.
San Diego-based Neurelis’ Valtoco (diazepam nasal spray) is a proprietary formulation incorporating the science of Intravail transmucosal absorption enhancement technology. The drug enables the noninvasive delivery of a range of drugs, while the company focuses on treating epilepsy.
Get the full story at our sister site, Drug Delivery Business News.